Press Releases Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06/03/2026			5-day change	1st Jan Change
212,500.00 ^KRW	+0.47%		-10.90%	+17.40%

02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
01-30	Celltrion Launches Autoimmune Drug Aptozma in Europe	MT

Press Releases

03-06	Celltrion to expand treasury share cancellation to 9.11 million shares: Prioritizing shareholder value amid heightened market uncertainty	PU
02-19	Celltrion : New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday	PU
02-12	Celltrion : to Submit Approx KRW 1.46Tn Treasury Share Cancellation Proposal to Shareholders’ Meeting; To Amend Articles Ahead of Commercial Act Revision to Enhance Transparency and Shareholder Value	PU
02-05	Celltrion : Reports Record-High Annual Revenue of KRW 4.1625Tn and Operating Profit of KRW 1.1685Tn in 2025… Signaling Continued Strong Growth Backed by High-Margin Newer Portfolio	PU
01-08	Celltrion And Sandoz Launch Their Aflibercept Biosimilars In Europe	AQ
11-05	FDA Grants Interchangeability Designation To Fresenius Kabi's And Celltrion's Denosumab Biosimilars	AQ
14/10/25	Celltrion Announces Launch Of AVTOZMA® (Tocilizumab-anoh) Intravenous Formulation In The United States	AQ
30/09/25	FDA Approves Biocon's Denosumab Biosimilars	AQ
16/06/25	Celltrion : announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients	PU
12/05/25	Celltrion : Investor Presentation May & June 2025	PU
29/04/25	Celltrion Adalimumab Biosimilar Granted Interchangeability Designation	AQ
28/03/25	Celltrion's STEQEYMA, now added to the Costco Member Prescription Program	AQ
28/03/25	Celltrion Wins Costco Formulary Listing For Its Recently Launched Ustekinumab	AQ
26/03/25	Celltrion Launches STEQEYMA® (ustekinumab-stba) In The United States	AQ
10/03/25	U.S. FDA approves Celltrion's OMLYCLO as the first and only biosimilar with interchangeability designation referencing XOLAIR	AQ
06/03/25	Celltrion : Investor Presentation March & April 2025	PU
25/02/25	Celltrion : FY2024, 4Q24 Earning Release Celltrion Inc.	PU
24/02/25	Celltrion Receives EC Approval for Avtozma, a Biosimilar to RoActemra	AQ
31/01/25	Amgen And Celltrion Settle Denosumab BPCIA Case	AQ
09/01/25	FDA Approves Celltrion's STEQEYMA (Ustekinumab-stba)	AQ
21/11/24	BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen	AQ
07/11/24	FDA Accepts ABLAs For Prolia® / Xgeva® Biosimilars From Organon And Teva	AQ
16/10/24	Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab, highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease	AQ
16/10/24	Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab	AQ
20/09/24	Celltrion Wins Brazilian Federal Tender For Trastuzumab For Fifth Consecutive Year	AQ